Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 3.70% is 60% above its 1-year average of 2.31%, near the high end of its 1-year range (-0.04%–3.70%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.44% above its 12-month average of 3.07%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 3.70%.
RETURN ON EQUITY (ROE)
3.70%
RETURN ON EQUITY (ROE) AVG TTM
3.07%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.44%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · FINANCIAL SERVICES
8.76%
median of 677 covered companies
CURRENT VS SECTOR MEDIAN
-57.75%
vs the sector median at left
Translational Development Acquisition Corp.
Market Cap
$266.50M
Return on Equity (ROE)
3.70%
TTM Avg
3.07%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.29M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.95M
Return on Equity (ROE)
14.45%
TTM Avg
12.94%
3Y Avg
10.71%
5Y Avg
11.49%
Market Cap
$267.82M
Return on Equity (ROE)
0.03%
TTM Avg
30.37%
3Y Avg
-4.86%
5Y Avg
-4.69%
Market Cap
$268.25M
Return on Equity (ROE)
8.74%
TTM Avg
6.88%
3Y Avg
7.54%
5Y Avg
7.88%
Market Cap
$264.51M
Return on Equity (ROE)
3.41%
TTM Avg
1.87%
3Y Avg
1.87%
5Y Avg
1.87%
Market Cap
$264.47M
Return on Equity (ROE)
3.49%
TTM Avg
2.30%
3Y Avg
2.30%
5Y Avg
2.30%
Market Cap
$264.38M
Return on Equity (ROE)
4.42%
TTM Avg
99.43%
3Y Avg
99.43%
5Y Avg
99.43%
Market Cap
$263.53M
Return on Equity (ROE)
183.78%
TTM Avg
142.95%
3Y Avg
142.95%
5Y Avg
142.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Translational Development Acquisition Corp. (TDAC) | $266.50M | 3.70% | 3.07% | N/A | N/A |
| Thunder Bridge Capital Partners V L (TBCVU)vs › | $266.29M | N/A | N/A | N/A | N/A |
| Hawthorn Bancshares, Inc. (HWBK)vs › | $265.95M | 14.45% | 12.94% | 10.71% | 11.49% |
| Kingstone Companies, Inc. (KINS)vs › | $267.82M | 0.03% | 30.37% | -4.86% | -4.69% |
| LCNB Corp. (LCNB)vs › | $268.25M | 8.74% | 6.88% | 7.54% | 7.88% |
| Oaktree Acquisition Corp. II (OACC)vs › | $264.51M | 3.41% | 1.87% | 1.87% | 1.87% |
| ProCap Acquisition Corp (PCAP)vs › | $264.47M | 3.49% | 2.30% | 2.30% | 2.30% |
| Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)vs › | $264.38M | 4.42% | 99.43% | 99.43% | 99.43% |
| Soren Acquisition Corp. (SORN)vs › | $263.53M | 183.78% | 142.95% | 142.95% | 142.95% |
| Cartesian Growth Corp. Iv (CGCF)vs › | $270.05M | N/A | N/A | N/A | N/A |
ROE
3.7%
ROA
3.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 3.70% |
| 2026-03-31 | 3.52% |
| 2025-12-31 | 3.63% |
| 2025-09-30 | 2.74% |
| 2025-06-30 | 1.77% |
| 2025-03-31 | 0.83% |
| 2024-12-31 | -0.04% |
